Antineoplastic Agents, Hormonal Concept

subject area of

• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer  Academic Article
• neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II  Academic Article
• A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen  Academic Article
• A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer  Academic Article
• A Phase II Study of Leuprolide in Advanced/Recurrent Endometrial Cancer  Academic Article
• A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer  Academic Article
• A Trial of Two Questions  Academic Article
• A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis  Academic Article
• A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer  Academic Article
• A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1  Academic Article
• A review of exemestane in the management of breast cancer  Academic Article
• A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer  Academic Article
• Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy  Academic Article
• Activity of fulvestrant in HER2-overexpressing advanced breast cancer  Academic Article
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer  Academic Article
• Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer  Conference Paper
• Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations  Academic Article
• Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis  Academic Article
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial  Academic Article
• Adjuvant endocrine therapy for breast cancer: a commentary.  Academic Article
• Adjuvant endocrine therapy for breast cancer: longer therapy and the need for personalized treatment--should we treat beyond the data?  Academic Article
• Adjuvant hormonal therapy for premenopausal breast cancer: incorporating clinical experience.  Academic Article
• American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction  Academic Article
• American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002  Academic Article
• An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer  Academic Article
• An update on adjuvant systemic therapy for elderly patients with early breast cancer  Academic Article
• Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data  Conference Paper
• Antihormone Therapy in Recurrent Metastatic Breast Cancer  Academic Article
• Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen  Academic Article
• Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review  Academic Article
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials  Academic Article
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials  Academic Article
• Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women  Academic Article
• Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial  Academic Article
• Attenuation of the Glucocorticoid Response during Ad5IL-12 Adenovirus Vector Treatment Enhances Natural Killer Cell–Mediated Killing of MHC Class I–Negative LNCaP Prostate Tumors  Academic Article
• Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer  Academic Article
• Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer  Academic Article
• CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned  Academic Article
• Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer  Academic Article
• Chemoprevention: Drug pricing and mortality  Academic Article
• Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer  Academic Article
• Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer  Academic Article
• Coagulopathy in a patient with nephrotic syndrome  Academic Article
• Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis  Academic Article
• Combining endocrine agents with chemotherapy: Which patients and what sequence?  Conference Paper
• Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial  Academic Article
• Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene  Academic Article
• Controversies in prostate cancer radiotherapy: consensus development.  Academic Article
• Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer  Academic Article
• Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?  Academic Article
• Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910  Academic Article
• Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers  Academic Article
• Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17  Academic Article
• Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies  Academic Article
• Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer  Academic Article
• Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93  Academic Article
• Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial  Academic Article
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials  Academic Article
• Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17  Academic Article
• Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference  Academic Article
• Endocrine symptoms to predict risk of recurrence?  Academic Article
• Endocrine therapy for breast cancer.  Academic Article
• Endocrine therapy of advanced disease: analysis and implications of the existing data.  Academic Article
• Endocrine therapy: is the first generation of targeted drugs the last?  Academic Article
• Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies  Academic Article
• Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women  Academic Article
• Endometrial Evaluation with Transvaginal US and Hysterosonography in Asymptomatic Postmenopausal Women with Breast Cancer Receiving Tamoxifen  Academic Article
• Endometrial cancer. Prevention, detection, management, and follow up.  Academic Article
• Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?  Academic Article
• Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer  Academic Article
• Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)  Academic Article
• Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions  Academic Article
• Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion  Academic Article
• GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model1Contributed equally and share first authorship.  Academic Article
• Growth in Children With Acute Lymphoblastic Leukemia During Treatment  Academic Article
• Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone  Academic Article
• High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial  Academic Article
• Hormone Replacement Therapy after Treatment for Breast Cancer: Physicians' Attitudes towards Randomized Trials  Academic Article
• Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer  Academic Article
• Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials  Academic Article
• Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer  Academic Article
• Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17  Academic Article
• Locally advanced breast cancer in octogenarian women  Academic Article
• Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues  Academic Article
• Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer  Academic Article
• Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005  Academic Article
• New-onset psychosis following androgen deprivation therapy for prostate cancer.  Academic Article
• Novel strategies for systemic treatment of endometrial cancer  Academic Article
• Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle  Academic Article
• Oligodendroglioma  Academic Article
• Ovarian ablation as adjuvant therapy for early-stage breast cancer  Academic Article
• Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer  Academic Article
• Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.  Academic Article
• PREDICTORS OF PATHOLOGICAL STAGE BEFORE NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY AND RADICAL PROSTATECTOMY  Academic Article
• PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide  Academic Article
• Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx  Academic Article
• Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer  Academic Article
• Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer  Academic Article
• Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01  Academic Article
• Postmenopausal breast cancer: is the short-term pain worth the long-term gain?  Academic Article
• Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer  Academic Article
• Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model  Academic Article
• Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement  Conference Paper
• Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario  Academic Article
• Prospective Validation of a 21-Gene Expression Assay in Breast Cancer  Academic Article
• Prospects of the Clinical Utilization of Melatonin  Academic Article
• Prostate cancer: risk categories and role of hormones and radiotherapy.  Academic Article
• Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE−/−:Ins2+/Akita mouse model  Academic Article
• Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question  Academic Article
• Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension  Academic Article
• Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14  Academic Article
• Rehabilitation in primary and metastatic brain tumours  Academic Article
• Remission of Macroglobulinemia during Anastrozole Treatment for Breast Cancer  Academic Article
• Resolution of Catamenial Epilepsy after Goserelin Therapy and Oophorectomy: Case Report of Presumed Cerebral Endometriosis  Academic Article
• Role of Gonadotropin-Releasing Hormone Analog in the Management of Male Metastatic Breast Cancer Is Uncertain  Academic Article
• Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds  Academic Article
• Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.  Academic Article
• Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study  Academic Article
• Sensitization of human melanoma cells by tamoxifen to apoptosis induction by pancratistatin, a nongenotoxic natural compound  Academic Article
• Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer  Academic Article
• Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated?  Academic Article
• Synergy of pancratistatin and tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria  Academic Article
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015  Academic Article
• Tamoxifen Derivatives for Delivery of the Antitumoral (DACH)Pt Group: Selective Synthesis by McMurry Coupling, and Biochemical Behaviour  Academic Article
• Tamoxifen May Be an Effective Adjuvant Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status  Academic Article
• Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?  Academic Article
• Tamoxifen for Breast Cancer Risk Reduction  Academic Article
• The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer  Academic Article
• The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review.  Academic Article
• The best use of adjuvant endocrine treatments  Conference Paper
• The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures  Academic Article
• The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma  Academic Article
• The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study.  Academic Article
• The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.  Academic Article
• The use and toxicity of steroids in the management of patients with brain metastases  Academic Article
• Therapeutic options in advanced prostate cancer: Present and future  Academic Article
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study  Academic Article
• Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial  Academic Article
• Trends in Hormonal Management of Prostate Cancer:  Academic Article
• Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient  Academic Article
• Words or Wisdom: Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer.  Academic Article
• [Medroxyprogesterone Acetate as Part of Palliative Care for Terminal-Stage Breast Cancer Patients--A Report of Two Cases].  Academic Article